Vakzine Projekt Management GmbH (VPM), founded in 2002, is a privately held company in the field of biomedical research and development. Within the last decade, VPM has been successfully developing promising biopharmaceutical candidates. Additionally, VPM offers tailor-made hands-on services and consultancy to biopharmaceutical enterprises, private funding organizations and research groups, based on their in-depth experience and a strong network of reliable partners. VPM has acted as sponsor or sponsor-representative for more than 15 clinical trials. Since July 2018 Serum Institute of India (SIIPL) is majority shareholder of VPM.
Main roles in project
VPM will support the Cruzivax project with their expertise in translational project management. Furthermore, VPM will be responsible for GxP consulting in the areas chemistry, manufacturing and control (CMC), and non-clinical and clinical development of the Traspain-based vaccine against T. cruzi. VPM has extensive experience with the conduct of regulatory/scientific advice meetings with national competent authorities. Therefore, VPM will perform, including the preparation, conduct and follow up, two scientific advice meetings with the national regulatory authority of Belgium. VPM will also act as sponsor (according to ICH E6 (R2) and Directive 2001/20/EC) of the phase 1 clinical trial.
Contact: Dr. Leander Grode
This project has received funding from the European Union’s Horizon 2020 research and innovationprogramme under grant agreement No 815418.